Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad – 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.com July 29, 2026 National Stock Exchange of India Ltd. (Scrip Code: DRREDDY) BSE Limited (Scrip Code: 500124) New York Stock Exchange Inc. (Stock Code: RDY) NSE IFSC Ltd. (Stock Code: DRREDDY) Dear Sir/Madam, Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 This is to inform you that the United States Food & Drug Administration (USFDA) today completed a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at our FTO-SEZ Process Unit-02, Srikakulam, Andhra Pradesh. The inspection was conducted between July 20, 2026, and July 29, 2026. We have been issued a Form 483 with three observations, which we will address within the stipulated timeline. This is for your information and records. Thanking you, Yours faithfully, For Dr. Reddy’s Laboratories Limited K Randhir Singh Company Secretary, Compliance Officer & Head-CSR